Min-Han Tan: More US cancer patients can now benefit from non-invasive ctDNA and ctRNA liquid biopsies
Min-Han Tan, CEO and Medical Director at Lucence, shared the post by Lucence, on LinkedIn:
“Very glad to share that more US cancer patients can now benefit from non-invasive ctDNA and ctRNA liquid biopsies, with expanded coverage!
So much thanks to Regence for helping more cancer patients access critical biomarker information for selecting treatments!”
Lucence shared this post on LinkedIn:
We’re glad to announce expanded access to our Liquid HALLMARK ctDNA and ctRNA liquid biopsy test for Regence health plan members across the Pacific Northwest and Intermountain regions.
1 in 2 eligible lung cancer patients in the United States do not receive precision medicine treatments due to limitations in biomarker testing (Sadik et al, JCO PO, 2022), as an example of the real problems faced by cancer patients.
This expanded coverage for ctDNA and RNA means more US cancer patients can receive liquid biopsy testing that provides essential biomarker testing.
Participation includes Regence’s commercial and Medicare Advantage plans where applicable, helping more cancer patients access critical testing.
Very glad to advance personalized cancer care together with our partners!”
Click here for more information.
Dr. Min-Han Tan is the CEO and Medical Director at Lucence, a precision oncology company. At Lucence, he leads a multidisciplinary team comprising experts in oncology, laboratory medicine, technology development, bioinformatics, and data science. Prior to his role at Lucence, Dr. Tan served as a Visiting Consultant in Medical Oncology at the National Cancer Centre Singapore.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023